Validated high-conviction buyer — this insider’s opportunistic purchases fall in a cohort whose buys have historically preceded above-benchmark moves. How we measure this ↗
Cencora director Dermot Durcan buys 4,000 shares at $274.19, adding 14.4% to holdings amid 28.1% pullback from 52-week high
Director Dermot Mark Durcan purchased 4,000 shares of Cencora at $274.19 on 2026-06-18, increasing his position from 27.8K to 31.8K shares. The purchase occurs while COR trades 28.1% below its 52-week high of $377.54 and has declined 17.1% over the past 90 days. Durcan's cross-ticker track record shows 2 prior open-market buys with a 100% 90-day win rate (avg +10.1% return), and his prior COR purchase on 2024-05-24 returned +10.1% at the 90-day mark. However, the stock's recent momentum—down 1.3% in 30 days and 17.1% in 90 days—contrasts with his historical pattern of well-timed accumulation across other securities, warranting attention to whether current fundamentals justify increased exposure or whether this represents purchase into an extended decline.
Director Dermot Mark Durcan bought 4,000 COR shares at $266.26; stock down 29.1% from 52-week high, prior COR buy returned +10.1% in 90 days.
Durcan's $1,065,040 purchase of 4,000 shares (16.8% increase to his 27.8K total holding) occurs as Cencora trades at $267.71, down 29.1% from its 52-week high of $377.54 and off 28.1% over the past 90 days. His prior open-market purchase of Cencora stock on 2024-05-24 generated a 90-day return of +10.1%, demonstrating a prior instance of well-timed buying at this ticker. Against a backdrop of revenue of $78.4B with 9.3% annual growth and a P/E of 20.44, the director is adding to his position during a period of significant price depreciation. The timing relative to the stock's recent downward trajectory and his demonstrated track record of successful buys at this company merits attention to whether this signals conviction in the company's recovery fundamentals.
